The direct link between PARP-1 hyperactivity and CDDP resistance we observed in TNBC cells is consistent with similar findings from non-small cell lung cancer (NSCLC) cells (32) and strengthen their roles in BER and HR pathways (33). This evidence concerns the gene PARP1 and non-small cell lung carcinoma.